Patients hospitalized with anti-glomerular basement membrane (anti-GBM) antibody disease, an autoimmune disease, are treated with a number of medications to stop the inflammation created by the disease. In this study, we want to see if adding the drug imlidifase to those usual treatments will stop the inflammation faster and helps reduce damage to the kidneys.
While you are being treated in the hospital, you would be placed at random , like the flip of a coin, into one of two groups. The first group will receive regular treatment, and the second group will receive regular treatment plus an infusion of an investigational drug (imlidifase). After your hospitalization, there will be 6 follow-up visits with a physical exam, blood draw, urine collection, and questions about your health.
free study drug
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA
Vimal Derebail
Medicine-Nephrology
Clinical or Medical
Interventional
Kidneys and Liver
Lungs and Breathing
22-1821
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
